{"id":"NCT01743729","sponsor":"Shire","briefTitle":"A Phase 3 Study to Evaluate the Efficacy of Lifitegrast in Subjects With Dry Eye","officialTitle":"A Phase 3, Multicenter, Randomized, Double-Masked and Placebo-Controlled Study Evaluating the Efficacy of a 5.0% Concentration of Lifitegrast Ophthalmic Solution Compared to Placebo in Subjects With Dry Eye Currently Using Artificial Tears (OPUS-2)","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2012-12-07","primaryCompletion":"2013-10-01","completion":"2013-10-01","firstPosted":"2012-12-06","resultsPosted":"2017-02-24","lastUpdate":"2021-06-23"},"enrollment":720,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"QUADRUPLE","primaryPurpose":"TREATMENT"},"conditions":["Dry Eye Disease"],"interventions":[{"type":"DRUG","name":"Lifitegrast","otherNames":["SAR 1118"]},{"type":"DRUG","name":"Placebo","otherNames":[]}],"arms":[{"label":"Lifitegrast","type":"EXPERIMENTAL"},{"label":"Placebo","type":"PLACEBO_COMPARATOR"}],"summary":"The purpose of the study is to evaluate the safety and efficacy of lifitegrast ophthalmic solution compared to placebo in the treatment of dry eye.","primaryOutcome":{"measure":"Change From Baseline in Inferior Corneal Fluorescein Staining Score to Day 84","timeFrame":"Baseline to Day 84","effectByArm":[{"arm":"Lifitegrast","deltaMin":2.39,"sd":0.763},{"arm":"Placebo","deltaMin":2.4,"sd":0.722}],"pValues":[{"comp":"OG000 vs OG001","p":"0.6186"}]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":6,"exclusionCount":9},"locations":{"siteCount":31,"countries":["United States"]},"refs":{"pmids":["26365210"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":3,"n":359},"commonTop":["Dysgeusia","Visual acuity reduced","Instillation site irritation","Instillation site reaction"]}}